Date: 2015-11-04
Type of information: Nomination
Compound:
Company: Arsanis (USA - MA)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On November 4, 2015, Arsanis announced that David Mantus has joined the company as Executive Vice President,
Regulatory Affairs, Clinical and Technical Operations. Dr. Mantus will oversee all facets of Arsanis’ global regulatory affairs, including filings and interactions with the major regulatory authorities around the world as well as clinical operations, manufacturing and quality. Dr. Mantus will report to Rene Russo, Arsanis’ Chief Development Officer.
Dr. Mantus joins Arsanis from BIND Therapeutics, where he served as Vice President, Regulatory Affairs and Quality Assurance. Prior to BIND, Dr. Mantus was Vice President of Regulatory Affairs at Cubist Pharmaceuticals. Prior to his time at Cubist, Dr. Mantus held various senior regulatory roles at Sention , Shire Biologics, and Parexel. He has also held positions at the Massachusetts Public Health Laboratory and Procter and Gamble Pharmaceuticals, as well as leading a regulatory affairs consulting practice. Dr. Mantus is a coauthor of a book on regulatory affairs, "FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics,” that is in its third edition. Dr. Mantus received his B.S. in Chemistry at the College of William and Mary, his M.S. and Ph.D. in Chemistry from Cornell University and was a post-doctoral research fellow in Biomedical Engineering at the University of Washington.
Financial terms:
Latest news:
